发明授权
US07250413B2 C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
有权
C-25氨基甲酸酯利福霉素衍生物,具有抗药性的微生物活性
- 专利标题: C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
- 专利标题(中): C-25氨基甲酸酯利福霉素衍生物,具有抗药性的微生物活性
-
申请号: US11114384申请日: 2005-04-26
-
公开(公告)号: US07250413B2公开(公告)日: 2007-07-31
- 发明人: Keith Combrink , Susan Harran , Daniel Denton , Zhenkun Ma
- 申请人: Keith Combrink , Susan Harran , Daniel Denton , Zhenkun Ma
- 申请人地址: US TX Dallas
- 专利权人: Cumbre Pharmaceuticals Inc.
- 当前专利权人: Cumbre Pharmaceuticals Inc.
- 当前专利权人地址: US TX Dallas
- 代理机构: Jackson Walker L.L.P.
- 主分类号: C07D498/08
- IPC分类号: C07D498/08 ; C07D519/00 ; A61K31/4709 ; A61K31/496 ; A61P31/04
摘要:
Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert their antimicrobial activity through a dual-function mechanism and therefore exhibit reduced frequency of resistance.
公开/授权文献
信息查询